Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7147062 | 0.93 | TSHR (0.49) | OPRM1CTRB1 | |
| SCHEMBL7146028 | 0.85 | POLB (0.46) | CTRB1MME | |
| SCHEMBL7162079 | 0.84 | PTGER4 (0.46) | OPRM1CTRB1 | |
| SCHEMBL7702739 | 0.82 | CTRB1 (0.69) | OPRM1CTRB1ACE | |
| SCHEMBL7148259 | 0.82 | CTRB1 (0.54) | CTRB1 | |
| SCHEMBL7144595 | 0.81 | POLB (0.48) | CTRB1MME | |
| SCHEMBL7141678 | 0.80 | KMT2A (0.47) | CTRB1 | |
| SCHEMBL7143663 | 0.80 | CYP3A4 (0.44) | CTRB1 | |
| SCHEMBL7147181 | 0.79 | POLB (0.47) | CTRB1ACE | |
| SCHEMBL7150010 | 0.78 | POLB (0.47) | CTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6541638-B2 | (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction | HOFFMAN-LA ROCHE INC. | 2003-04-01 | — | — | US | disclosed |
| US-20020049243-A1 | Pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049243-A1 | Pyrrolidine derivatives | PREP, PEPD, DNPEP | OPRM1 2833/4885CTRB1 283/4885ITGB1 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.